DDInter336 DDInter1763
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Celecoxib {u} (Compound) palliates {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Temsirolimus
Celecoxib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Celecoxib {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Celecoxib {u} (Compound) upregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Celecoxib {u} (Compound) downregulates {v} (Gene) RBM34
RBM34 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Celecoxib {u} (Compound) causes {v} (Side Effect) Ecchymosis
Ecchymosis {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Celecoxib {u} (Compound) palliates {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Celecoxib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Celecoxib {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) covaries with {v} (Gene) YRDC
YRDC {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Celecoxib {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is associated with {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Temsirolimus
Celecoxib (Compound) palliates kidney cancer (Disease) and kidney cancer (Disease) is treated by Temsirolimus (Compound)
Celecoxib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Celecoxib (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Temsirolimus (Compound)
Celecoxib (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is downregulated by Temsirolimus (Compound)
Celecoxib (Compound) downregulates RBM34 (Gene) and RBM34 (Gene) is downregulated by Temsirolimus (Compound)
Celecoxib (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Temsirolimus (Compound)
Celecoxib (Compound) palliates kidney cancer (Disease) and kidney cancer (Disease) is treated by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Celecoxib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Celecoxib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) covaries with YRDC (Gene) and YRDC (Gene) is downregulated by Temsirolimus (Compound)
Celecoxib (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is associated with kidney cancer (Disease) and kidney cancer (Disease) is treated by Temsirolimus (Compound)